Literature DB >> 20960476

Subcutaneous insulin-like growth factor-1 treatment in spinocerebellar ataxias: an open label clinical trial.

Javier Arpa, Irene Sanz-Gallego, Josmarlin Medina-Báez, Luis Valmor Cruz Portela, Laura Bannach Jardim, Ignacio Torres-Aleman, Jonas Alex Morales Saute.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20960476     DOI： 10.1002/mds.23423

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  15 in total

Review 1.  Generating new neurons to circumvent your fears: the role of IGF signaling.

Authors:  R C Agis-Balboa; A Fischer
Journal:  Cell Mol Life Sci       Date:  2013-03-30       Impact factor: 9.261

Review 2.  Current concepts in the treatment of hereditary ataxias.

Authors:  Pedro Braga Neto; José Luiz Pedroso; Sheng-Han Kuo; C França Marcondes Junior; Hélio Afonso Ghizoni Teive; Orlando Graziani Povoas Barsottini
Journal:  Arq Neuropsiquiatr       Date:  2016-03       Impact factor: 1.420

3.  Long-term treatment with thiamine as possible medical therapy for Friedreich ataxia.

Authors:  Antonio Costantini; Tiziana Laureti; Maria Immacolata Pala; Marco Colangeli; Simona Cavalieri; Elisa Pozzi; Alfredo Brusco; Sandro Salvarani; Carlo Serrati; Roberto Fancellu
Journal:  J Neurol       Date:  2016-08-03       Impact factor: 4.849

Review 4.  The many faces of insulin-like peptide signalling in the brain.

Authors:  Ana M Fernandez; Ignacio Torres-Alemán
Journal:  Nat Rev Neurosci       Date:  2012-03-20       Impact factor: 34.870

Review 5.  Treatment Options in Degenerative Cerebellar Ataxia: A Systematic Review.

Authors:  Harini Sarva; Vicki Lynn Shanker
Journal:  Mov Disord Clin Pract       Date:  2014-06-12

Review 6.  Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.

Authors:  Kritika Raj; Ravi Shankar Akundi
Journal:  Mol Neurobiol       Date:  2021-02-24       Impact factor: 5.590

7.  Frataxin deficiency unveils cell-context dependent actions of insulin-like growth factor I on neurons.

Authors:  Carolina Franco; Silvia Fernández; Ignacio Torres-Alemán
Journal:  Mol Neurodegener       Date:  2012-10-05       Impact factor: 14.195

Review 8.  Autosomal dominant cerebellar ataxia type III: a review of the phenotypic and genotypic characteristics.

Authors:  Shinsuke Fujioka; Christina Sundal; Zbigniew K Wszolek
Journal:  Orphanet J Rare Dis       Date:  2013-01-18       Impact factor: 4.123

9.  IGF-1 in Friedreich's Ataxia - proof-of-concept trial.

Authors:  Irene Sanz-Gallego; Ignacio Torres-Aleman; Javier Arpa
Journal:  Cerebellum Ataxias       Date:  2014-07-04

10.  IGF-1 in autosomal dominant cerebellar ataxia - open-label trial.

Authors:  Irene Sanz-Gallego; Francisco J Rodriguez-de-Rivera; Irene Pulido; Ignacio Torres-Aleman; Javier Arpa
Journal:  Cerebellum Ataxias       Date:  2014-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.